Tonix Pharmaceuticals Holding (TNXP) Capital Expenditures (2011 - 2026)

Tonix Pharmaceuticals Holding has reported Capital Expenditures for 16 years, with the latest figure at -$1.5 million in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 377.61% year-over-year to -$1.5 million in Q2 2026; TTM through Jun 2026 was $5.1 million, a 838.53% increase from a year earlier, with the FY2025 full-year figure at $3.4 million, up 2707.5% from the prior year.
• Capital Expenditures was -$1.5 million for Q2 2026 at Tonix Pharmaceuticals Holding, down from $3.7 million in the prior quarter.
• The five-year high for Capital Expenditures was $20.2 million in Q1 2022, with the low at -$1.5 million in Q2 2026.
• Average Capital Expenditures over 5 years is $3.6 million, with a median of $1.8 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Capital Expenditures surged 62366.67% in 2025, then slumped 377.61% in 2026.
• Over 5 years, Capital Expenditures stood at $4.7 million in 2022, then plunged by 90.62% to $438000.0 in 2023, then tumbled by 99.32% to $3000.0 in 2024, then soared by 62366.67% to $1.9 million in 2025, then plunged by 178.07% to -$1.5 million in 2026.
• The last three Capital Expenditures figures came in at -$1.5 million (Q2 2026), $3.7 million (Q1 2026), and $1.9 million (Q4 2025), per Business Quant data.